节点文献

血清多肽图用于急性白血病诊断及疗效评价的研究

Investigation of Serum Peptide Pattern for Acute Leukemia Diagnosis and Therapeutic Efficacy Evaluation

【作者】 梁婷婷

【导师】 王冠军;

【作者基本信息】 吉林大学 , 内科学, 2011, 博士

【摘要】 急性白血病是一类造血干细胞异常的血液系统恶性肿瘤,严重威胁人类的生命。由于造血干细胞在发育过程中一系列基因的改变,从而使造血干细胞不能正常分化,对增殖调控因子失去反应能力,造成大量原始的造血干细胞积聚在骨髓、外周血和其他组织器官中,抑制正常造血细胞生长,进而产生一系列与此相关的临床表现,如贫血、出血、感染、肝脾及淋巴结肿大等表现。目前临床上通过骨髓细胞形态学、免疫学、细胞遗传学和分子生物学方法的联合应用对急性白血病做出诊断。治疗后,通过骨髓细胞形态学或其他分子生物学方法进行早期疗效评价,指导下一步治疗和做出预后评价。骨髓来源的检测分析需要在局部麻醉的条件下抽取病人骨髓,创伤性大、耗时长,而且存在一定的操作风险,目前尚缺乏一种无创、省时、灵敏度和特异性高的血清学诊断和评价方法。血清/血浆检验具有创伤性小、花费少、易获得,处理简便的特点,而且在各种生理或病理状态下,血清/血浆中的蛋白质常有质或量的变化,因此广泛用于多种疾病诊断标志物的研究。血清多肽图(简称血肽图)方法是一种全新的诊断方法,以质谱作为主要检测手段,可检测到大量的血清多肽,根据谱图模式的差异做出诊断。血清多肽谱图技术用于肿瘤诊断研究之初就取得了令人振奋的结果。2002年发表在Lancet上的一篇题为“血清多肽组质谱扫描技术成功预警早期卵巢癌”的论文阐述了血清多肽谱用于肿瘤的诊断。此论文采用生物质谱技术比较了疾病组和对照组的血清多肽谱图模式,根据两组之间的差异特征分别对疾病组和对照组进行诊断。结果显示,50例卵巢癌患者全部被正确检出,而其中18例为Ⅰ期卵巢癌患者。该方法检测卵巢癌分别获得了100%的敏感性、95%的特异性和94%的阳性预测值,不仅优于传统的CA125检测,而且对于早期卵巢癌的诊断也十分有效。随后,国际上陆续发表了血清多肽图技术用于肿瘤诊断的论文。如,2006年初来至于Memorial Sloan-Kettering肿瘤中心的Villanueva等在The Journal of Clinical Investigation杂志发表了多肽分离技术与MALDI-TOF-MS联合诊断膀胱癌、乳腺癌和前列腺癌。2006年底Nature杂志上发表了对该文章的一篇评论,评论中对此方法给予了肯定。同时,Villanueva等再次在Molecular & Cellular Proteomics杂志上发表了利用上述技术诊断转移性甲状腺癌的论文。此外,相关论文也在Clinical Cancer Research, Journal of Clinical Oncology以及Clinical Chemistry等杂志发表。值得一提的是这一方法不仅用于肿瘤的诊断,也可用于其它疾病的诊断。2006年Lancet上发表了一篇题为“血清蛋白质组谱图法检测结核诊断标志物”的论文,与传统的诊断方法相比,结核病诊断的特异性和灵敏度均超过95%。这些研究成果表明人的血清多肽,尤其是低分子量的多肽中存在大量与肿瘤诊断相关的重要信息,因此研究血清多肽谱图比传统研究单个肿瘤诊断标记物更具有优势和前景。血清蛋白和多肽的提取是蛋白质组学用于疾病诊断研究的关键技术环节。在蛋白质组学研究中,双向凝胶电泳是蛋白质分离技术的典型代表。该技术充分利用了蛋白质的等电点和分子量两大物理特性将样品中的蛋白质复合物分离。但是它需要的样品量大、可检测的蛋白范围有限、重复性差以及耗时费力,并不适于临床诊断研究。大量血清多肽研究采用蛋白质芯片分离技术,该技术不需要对样品做预处理,样品点靶后可直接进行质谱检测分析,但是检测后的样品无法洗脱进行后续的鉴定分析,而且芯片制备工艺复杂、价格昂贵,限制了蛋白芯片的应用。随着高分辨质谱MALDI-TOF-MS应用于肿瘤诊断研究,多种血清蛋白或多肽分离方法可以与其联用,弥补了蛋白质芯片的不足。而超高分辨率和灵敏度的FT-ICR-MS质谱仪的出现,使血清多肽的鉴定成为可能。磁珠分离体系是近年兴起并广泛用于血清多肽制备的方法。它的组成通常包括磁性内核和表面的高分子外壳。其表面的大分子决定了结合蛋白质/多肽的性质和种类。由于磁珠表面积较大,结合能力高,因此具有较高的提取效率,而且操作简便,重复性较好,已用于疾病诊断的蛋白质组学研究。在本研究中,我们选用金属螯合磁珠和高分辨质谱MALDI-TOF-MS作为急性白血病血清多肽谱图研究的技术体系。我们对磁珠分离和质谱检测的稳定性和重复性进行了实验评价,评价结果显示上述体系稳定,达到了国际要求。应用这一技术体系对147例急性白血病和107例对照血清进行检测,获得了两组的血清多肽谱图,通过Biosun_MS生物信息学软件中的支持向量机(support vector machine, SVM)算法和t检验分析,初步建立了急性白血病的血清多肽图诊断模型,该诊断模型的诊断特异性和敏感性分别为100%和97%。进一步分析55个特征多肽(P<0.001)的峰强度在初治急性白血病、急性白血病血液学完全缓解、急性白血病分子缓解和健康对照组的分布趋势发现,两个血请多肽m/z 1865.13和1778.05的峰强度随着急性白血病治疗缓解程度提高有所降低,尤其在分子缓解时二者强度明显减低。上述趋势也同样存在于M3型急性白血病经治疗达分子缓解时,两个多肽的峰强度明显减低接近于健康水平,提示这两个多肽具有微小残留病监测的潜力。FT-ICR-MS质谱测序结果证明这两个多肽为补体C3f片段。此外,该技术体系还用于急性白血病的疗效评价研究,研究中通过检测分析30例初治急性白血病及其治疗两个疗程后达血液学完全缓解的血清,获得了初治与血液学缓解后的血清多肽谱图,通过Biosun_MS生物信息学软件中的SVM算法和检验分析,初步建立了急性白血病疗效评价的血清多肽谱图模型,该诊断模型的诊断特异性和敏感性分别为90%和100%。上述研究结果表明血清多肽谱图模式能够反映急性白血病的病理状态,为我们进一步的研究提供了依据。综合我们的研究结果,本研究的主要结论如下:①本研究初步建立了急性白血病血清多肽谱图诊断模型和疗效评价模型,同时发现了与微小残留病监测相关的血清多肽。②测序分析所获得的7个特征血清多肽序列为急性白血病机制的探讨提供了线索。本研究的创新之处在于将血清多肽谱图模式诊断技术引入急性白血病研究,发现并探讨了其在急性白血病诊断、微小残留病监测和疗效评价方面的应用潜力。

【Abstract】 Acute leukemia (AL) is a malignant blood disease with abnormal hematopoietic stem cells, which can cause severe health problems, even death. The hematopoietic cells with gene defects in AL patients lost the ability of normal differentiation and response to normal regulators of proliferation. Finally, many primary hematopoietic stem cells cumulate in the bone marrow, peripheral blood and other organs, which inhibit normal hematopoietic cells growth and cause a series of clinical manifestation, such as anemia, haemorrhage, infection, hepatosplenomegaly and lymphadenectasis. Now the diagnosis of AL can be made on the bone marrow analysis, including morphology, immunology, cytogenetics and molecular genetics analysis. After treatment, the diagnostic methods mentioned above also can be used for the evaluation of early therapeutic efficacy that is essential for further treatment and prognostic assessment. However, AL patients should undergo bone marrow aspiration under local anesthesia before analysis, which is invasive, time-consuming and risky, so a minimally invasive, fast and sensitive approach for serum diagnosis and evaluation is necessary.The characteristics of serum examination are minimally invasive, low cost, easy acquiring and processing. Also the serum protein level under disease state is different from the level in healthy state. Thus, serum is a good specimen to be generally used in disease marker research. Serum peptide pattern is a novel diagnostic method, in which mass spectrometry is used to generate serum peptide profiles, and the diagnosis will be given based on the peptide pattern difference by bioinformatics software. The researchers have obtained a lot of exciting results when this method was applied for the investigation in tumor diagnosis. In 2002, a paper named "Use of proteomic patterns in serum to identify ovarian cancer" was published in Lancet journal. In this paper, the serum peptide pattern was used for ovarian cancer diagnosis. They analyzed the peptide pattern of healthy control group and disease group to diagnose ovarian cancer by mass spectrometry and bioinformatics software. The results showed that all 55 ovarian cancer patients were correctly diagnosis, and 18 of 55 cases were stage I ovarian cancer patients. The sensitivity, specificity and positive predictive value is 100%, 95%,94%, respectively. It suggested that this method was better than traditional detection of CA125 and was also very effective in the diagnosis of early stage ovarian cancer. Later, several papers about serum peptide pattern for tumor diagnosis were published, such as 2006, Villanueva et al published their research in bladder cancer, breast cancer, and prostate cancer diagnosis on The Journal of Clinical Investigation. At the end of 2006, a comment on this paper was given on Nature. In the comment, the author shows a positive attitude toward the development and application of this serum peptide technique in future. Also, there is another paper about serum peptide technique used for metastatic thyroid cancer diagnosis published by Villanueva et al on the Molecular & Cellular Proteomics journal. Additionally, serum peptide technique related papers were also published on the Clinical Cancer Research, Journal of Clinical Oncology and Clinical Chemistry. It is worth mentioning that this technique not only can be used in tumor diagnosis, but also used in other disease research, such as tuberculosis. In 2006 Lancet, a paper "Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum" was published. The results revealed that serum peptide technique obtained more than 95% specificity and sensitivity in diagnosis of tuberculosis, which is better than the traditional diagnostic method. All of these results indicate that human serum peptides, especially low molecular weight peptides contain important information for tumor diagnosis. It is thus more useful and helpful to do research in serum peptide patterns than in traditional single markerSerum protein and peptide isolation is the key point in proteomics research. 2-DE is a typical protein isolation technique in proteomics research. It can isolate intact protein from complex according to their physical properties, eg, isoelectric point and molecular weight. But it requires large sample quantities, has a limited dynamic range for protein detection, is poorly reproducible and labor intensive, thus it is not fit for clinical diagnosis. Recently, protein chip has been applied in serum peptide research. The sample without preparation can be used for detection directly. However, this advantage is also the disadvantage of this method. Because the samples can not be further identified. Also, protein chip is so sophisticated and high cost that limits its application. Given high-resolution MALDI-TOF-MS has been developed for tumor research, a variety of protein/peptide isolation methods can be combined to overcome the problems of protein chip. Moreover, the emergence of high resolution and sensitivity FT-ICR-MS makes the serum peptide identification to be possible. Magnetic beads based technique is newly developed for serum peptide preparation. This method uses different chemical chromatographic surfaces on the out layer of magnetic beads to selective purify certain subsets of proteins/peptides. Since magnetic beads have the characteristics of large surface area, high binding capacity, high efficiency, easy processing and good reproducibility, it has been combined with MALDI-TOF-MS detection and utilized in disease proteomic research.In this study, magnetic beads and high-resolution MALDI-TOF-MS were used as the main techniques for the research in serum peptide pattern of acute leukemia. The evaluation about stability and reproducibility of this technique system was performed at beginning. The results showed this system was stable and accord with the standard. We further used this system to analyze AL group and healthy control group sera, and obtained the serum peptide profiles. After analysis by bioinformatics software Biosun_MS (SVM algorithm and t-test), a diagnostic model based on serum peptide pattern was set up for diagnosing acute leukemia. This model achieved 100% specificity and 97% sensitivity. Further intensity analysis of 55 features (P<0.001) in primary AL, AL with hematologic complete remission, AL with molecular remission and healthy controls, two peptides m/z 1865.13 and 1778.05 were found decreased in their relative intensity with the increase of remission degree. In M3-AL, their relative intensities also decreased and were close to normal state after molecular remission. With FT-ICR-MS detection, both the peptides were identified as fragments of complement C3f. Furthermore, this system was also applied for the assessment of treatment efficacy in acute leukemia. Through analyzing primary AL and their hematologic complete remission sera, we obtained the serum peptide profiles. After analysis by bioinformatics software Biosun_MS (SVM algorithm and t-test), a diagnostic model based on serum peptide pattern was set up for the assessment of treatment efficacy in acute leukemia, and got 100% sensitivity and 90% specificity.These results manifested that serum peptide pattern could reflect the pathological state of disease, which will be the evidence for our further study. The conclusions of our investigation were as following:(1) A model for acute leukemia diagnosis and a model for treatment efficacy evaluation in acute leukemia have been built, respectively. Moreover, two peptides were found to be related with minimal residual disease monitoring. (2) 7 feature peptide sequences we got in this research could be helpful for further discussion about mechanisms of acute leukemia. The novelty of this study is the application of serum peptide techniques in acute leukemia research as well as investigating and discussing the potential role of serum peptide technique in minimal residual disease monitoring and therapeutic evaluation.

  • 【网络出版投稿人】 吉林大学
  • 【网络出版年期】2011年 09期
节点文献中: 

本文链接的文献网络图示:

本文的引文网络